Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) have earned an average rating of “Hold” from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $41.40.
A number of brokerages recently issued reports on CERE. JPMorgan Chase & Co. raised their price target on Cerevel Therapeutics from $25.00 to $45.00 and gave the stock a “neutral” rating in a research note on Thursday, December 28th. Jefferies Financial Group reissued a “hold” rating and set a $45.00 price target (up from $40.00) on shares of Cerevel Therapeutics in a research note on Friday, December 22nd. Finally, Mizuho raised their price target on Cerevel Therapeutics from $25.00 to $45.00 and gave the stock a “neutral” rating in a research note on Friday, February 16th.
Get Our Latest Stock Report on Cerevel Therapeutics
Insider Activity
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Pacific Capital Wealth Advisors Inc. purchased a new position in Cerevel Therapeutics during the 4th quarter worth $71,000. KBC Group NV purchased a new position in Cerevel Therapeutics during the 4th quarter worth $88,000. Centaurus Financial Inc. purchased a new position in Cerevel Therapeutics during the 4th quarter worth $119,000. Royal Bank of Canada grew its stake in Cerevel Therapeutics by 19.4% during the 3rd quarter. Royal Bank of Canada now owns 2,959 shares of the biotechnology company’s stock worth $83,000 after buying an additional 480 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in Cerevel Therapeutics by 59.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,262 shares of the biotechnology company’s stock worth $135,000 after buying an additional 1,588 shares during the last quarter. 87.73% of the stock is currently owned by hedge funds and other institutional investors.
Cerevel Therapeutics Stock Performance
NASDAQ CERE opened at $41.70 on Tuesday. The stock has a market capitalization of $7.57 billion, a PE ratio of -16.68 and a beta of 1.48. The business has a 50 day simple moving average of $41.96 and a two-hundred day simple moving average of $35.87. The company has a debt-to-equity ratio of 0.50, a current ratio of 10.92 and a quick ratio of 10.92. Cerevel Therapeutics has a 1-year low of $19.59 and a 1-year high of $43.59.
Cerevel Therapeutics Company Profile
Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.
Recommended Stories
- Five stocks we like better than Cerevel Therapeutics
- Election Stocks: How Elections Affect the Stock Market
- The Charles Schwab Company Can Hit New Highs
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for Cerevel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerevel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.